How AI Drug Discovery Will Impact GSK (LSE:GSK) Investors
- Chai Discovery reported in early October 2026 that GSK will use its AI protein folding and design models across GSK’s discovery pipeline after internal tests found binders to all evaluated targets.
- Wave Life Sciences disclosed a new GalNAc siRNA hepatology candidate selected by GSK, signalling external partners are feeding directly into GSK’s pipeline while triggering a $12 million milestone and larger potential payments.
- We will look at how GSK’s investment narrative around AI enabled R&D efficiency evolves after the expanded Chai Discovery collaboration.
GSK Investment Narrative Recap
To own GSK today, you need to believe the vaccines and specialty medicines engine, including oncology and long acting HIV, can offset future patent expiries and pricing pressure in general medicines. The recent Chai Discovery deal sits squarely in that story. It supports GSK’s push to use data and AI to move candidates through preclinical work more efficiently.
The most important near term swing factor still looks like execution on late stage programs and the Accelerate Growth cost saving plan, not this one AI alliance on its own. The biggest risk remains pipeline setbacks or delayed launches that leave GSK more exposed to loss of exclusivity and ongoing U.S. pricing reform.
The Wave Life Sciences update in late September is tightly linked to this. GSK selecting a SpiNA design GalNAc siRNA hepatology candidate and moving it into its own development pipeline shows external partners are already feeding assets into future specialty medicines. That sits alongside the AI work with Chai rather than replacing it.
For catalysts, you are watching how quickly that Wave program and three additional collaboration projects approach further milestones, and whether they help diversify beyond HIV and vaccines before key patents roll off. Operationally, each partnered asset that advances reduces pressure on any single program and partly mitigates the risk of another camlipixant style discontinuation.
Based on current analyst modelling, GSK's story lines up to £37.2b in revenue and £7.0b in earnings by 2029, built on a projected 3.9% yearly increase in revenue and an earnings rise of about £2.2b from £4.8b today.
Uncover why GSK's fair value indicates a 23% potential upside to its current price that could narrow quickly.
Exploring Other Perspectives
Some of the lowest GSK forecasts turn the AI story on its head. Those analysts focus on the risk that heavier data and partnership spending does not translate into better late stage success, which keeps pressure on earnings. They were pencilling in around £35.4b revenue and £6.5b earnings by 2029. That view is more cautious than consensus and was set before the Chai Discovery news, so you may want to compare these assumptions with your own and decide which version of GSK’s future feels closer to your expectations.
Explore 5 other GSK fair value estimates, including one that suggests as much as 7% downside from the current price.
The Verdict Is Yours
Don't just follow the ticker; dig into the data and build a conviction that's truly your own.
- A great starting point for your GSK research is our analysis highlighting 4 key rewards and 3 important warning signs that could impact your investment decision.
- See our latest analysis for GSK. The report includes a comprehensive fundamental analysis summarized in a single visual, the Snowflake, making it easy to evaluate GSK's overall financial health at a glance.
Looking for more investment ideas beyond GSK?
Once you have a view on GSK, it can help to widen the lens and compare it with other opportunities that match your risk tolerance and income needs. The Simply Wall St Screener lets you do that quickly by filtering for fundamentals that actually matter to you.
- If you want potential mispricings backed by strong business quality, start with a curated set of 7 high quality undervalued stocks that already combine solid fundamentals with attractive valuations.
- If capital preservation comes first, focus on resilience and financial strength by scanning a 4 resilient stocks with low risk scores that aims to keep balance sheets and risk scores front and center.
- If you prefer robust cash generation and income potential, zero in on a 1 dividend fortresses that screens for higher yielding payers while still watching for fundamental support.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com